Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children

American Journal of Kidney Diseases

Volumn 61, Issue 1, 2013, Pages 22-32

  Laskin, Benjamin L ^a   Goebel, Jens ^b   Starke, Jeffrey R ^c   Schauer, Daniel P ^d   Eckman, Mark H ^d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

children; Cost effectiveness; nephrotic syndrome; tuberculosis

Indexed keywords

PREDNISONE;

ARTICLE; CASE REPORT; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; GOLD STANDARD; HIDDEN MARKOV MODEL; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MALE; NEPHROTIC SYNDROME; PRESCHOOL CHILD; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RISK FACTOR; SCREENING; SENSITIVITY AND SPECIFICITY; STEROID THERAPY; TUBERCULIN TEST;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MARKOV CHAINS; MASS SCREENING; NEPHROTIC SYNDROME; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STEROIDS; TUBERCULIN TEST;

EID: 84871242222     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.06.004     Document Type: Article

References (82)

1. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Controlling tuberculosis in the United States Am J Respir Crit Care Med 172 9 2005 1169 1226
2. World Health Organization Global tuberculosis control 2011 http://www.who.int/tb/publications/global-report/2011/gtbr11-full.pdf Accessed December 12, 2011
3. A.T. Cruz, A.M. Geltemeyer, J.R. Starke, J.A. Flores, E.A. Graviss, K.C. Smith Comparing the tuberculin skin test and T-SPOT.TB blood test in children Pediatrics 127 1 2011 e31 e38
4. C.R. Horsburgh Jr, S. Goldberg, J. Bethel Latent TB infection treatment acceptance and completion in the United States and Canada Chest 137 2 2010 401 409
5. G.H. Mazurek, J. Jereb, A. Vernon, P. LoBue, S. Goldberg, K. Castro Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010 MMWR Recomm Rep 59 RR-5 2010 1 25
6. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents Pediatrics 114 4, pt 3 2004 1175 1201
7. A.T. Cruz, J.R. Starke Pediatric tuberculosis Pediatr Rev 31 1 2010 13 25
8. F. Tubach, D. Salmon, P. Ravaud Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies Registry Arthritis Rheum 60 7 2009 1884 1894
9. F. Wolfe, K. Michaud, J. Anderson, K. Urbansky Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy Arthritis Rheum 50 2 2004 372 379 (Pubitemid 38198820)
10. W.G. Dixon, K.L. Hyrich, K.D. Watson Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) Ann Rheum Dis 69 3 2010 522 528
11. J. Keane, S. Gershon, R.P. Wise Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 15 2001 1098 1104
12. J.R. Cisneros, K.M. Murray Corticosteroids in tuberculosis Ann Pharmacother 30 11 1996 1298 1303 (Pubitemid 26367453)
13. Targeted tuberculin testing and treatment of latent tuberculosis infection Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC) Am J Respir Crit Care Med. 161 4, pt 2 2000 S221 S247
14. U. Mack, G.B. Migliori, M. Sester LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement Eur Respir J 33 5 2009 956 973
15. D.S. Gipson, S.F. Massengill, L. Yao Management of childhood onset nephrotic syndrome Pediatrics 124 2 2009 747 757
16. R. Gbadegesin, W.E. Smoyer Nephrotic syndrome D.F. Geary, F. Schaefer, Comprehensive Pediatric Nephrology 2008 Mosby Elsevier Philadelphia, PA 205 218
17. E.M. Hodson, S.I. Alexander, N. Graf Steroid-sensitive nephrotic syndrome D.F. Geary, F. Schaefer, Comprehensive Pediatric Nephrology 2008 Mosby Elsevier Philadelphia, PA 239 256
18. Z. Taylor, S.M. Marks, N.M. Rios Burrows, S.E. Weis, R.L. Stricof, B. Miller Causes and costs of hospitalization of tuberculosis patients in the United States Int J Tuberc Lung Dis 4 10 2000 931 939
19. E.M. Hodson, J.C. Craig, N.S. Willis Evidence-based management of steroid-sensitive nephrotic syndrome Pediatr Nephrol 20 11 2005 1523 1530 (Pubitemid 41554459)
20. S. Lockman, J.W. Tappero, T.A. Kenyon, D. Rumisha, R.E. Huebner, N.J. Binkin Tuberculin reactivity in a pediatric population with high BCG vaccination coverage Int J Tuberc Lung Dis 3 1 1999 23 30 (Pubitemid 29136557)
21. D.A. Lewinsohn, M.N. Lobato, J.A. Jereb Interferon-gamma release assays: new diagnostic tests for Mycobacterium tuberculosis infection, and their use in children Curr Opin Pediatr 22 1 2010 71 76
22. F.A. Sonnenberg, J.R. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 4 1993 322 338 (Pubitemid 24013155)
23. A.K. Detjen, T. Keil, S. Roll Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis Clin Infect Dis 45 3 2007 322 328 (Pubitemid 47101028)
24. M.A. de Perio, J. Tsevat, G.A. Roselle, S.M. Kralovic, M.H. Eckman Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers Arch Intern Med 169 2 2009 179 187
25. M. Sadatsafavi, N. Shahidi, F. Marra A statistical method was used for the meta-analysis of tests for latent TB in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy J Clin Epidemiol 63 3 2010 257 269
26. A. Pooran, H. Booth, R.F. Miller Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis BMC Pulm Med 10 2010 7
27. V.J. Flaherman, T.C. Porco, E. Marseille, S.E. Royce Cost-effectiveness of alternative strategies for tuberculosis screening before kindergarten entry Pediatrics 120 1 2007 90 99 (Pubitemid 47036245)
28. M. Pai, A. Zwerling, D. Menzies Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update Ann Intern Med 149 3 2008 177 184
29. D. Menzies, M. Pai, G. Comstock Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research Ann Intern Med 146 5 2007 340 354 (Pubitemid 351650594)
30. G.M. Berkel, F.G. Cobelens, G. de Vries, I.W. Draayer-Jansen, M.W. Borgdorff Tuberculin skin test: estimation of positive and negative predictive values from routine data Int J Tuberc Lung Dis 9 3 2005 310 316 (Pubitemid 40392948)
31. D.N. Rose, C.B. Schechter, J.J. Adler Interpretation of the tuberculin skin test J Gen Intern Med 10 11 1995 635 642
32. R.E. Huebner, M.F. Schein, J.B. Bass Jr The tuberculin skin test Clin Infect Dis 17 6 1993 968 975 (Pubitemid 23358739)
33. H. Froehlich, L.M. Ackerson, P.A. Morozumi Targeted testing of children for tuberculosis: validation of a risk assessment questionnaire Pediatrics 107 4 2001 E54
34. P.O. Ozuah, T.P. Ozuah, R.E. Stein, W. Burton, M. Mulvihill Evaluation of a risk assessment questionnaire used to target tuberculin skin testing in children JAMA 285 4 2001 451 453 (Pubitemid 32098029)
35. R. Diel, R. Loddenkemper, A. Nienhaus Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis Chest 137 4 2010 952 968
36. J. Mancuso, D. Niebuhr, M.R. Krauss, C. Dabbs, K. Anderson Cost-effectiveness of tuberculosis screening in health care workers is not robust [letter] Arch Intern Med 169 14 2009 1336 author reply 1336-1337
37. D.E. Bennett, J.M. Courval, I. Onorato Prevalence of tuberculosis infection in the United States population: the National Health and Nutrition Examination Survey, 1999-2000 Am J Respir Crit Care Med 177 3 2008 348 355 (Pubitemid 351198380)
38. J.C. Mohle-Boetani, B. Miller, M. Halpern School-based screening for tuberculous infection A cost-benefit analysis JAMA 274 8 1995 613 619
39. C.R. Driver, S.E. Valway, M.F. Cantwell, I.M. Onorato Tuberculin skin test screening in schoolchildren in the United States Pediatrics 98 1 1996 97 102 (Pubitemid 26226980)
40. C.R. Gounder, C.R. Driver, J.N. Scholten, H. Shen, S.S. Munsiff Tuberculin testing and risk of tuberculosis infection among New York City schoolchildren Pediatrics. 111 4, pt 1 2003 e309 e315
41. M.N. Lobato, P.C. Hopewell Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis Am J Respir Crit Care Med 158 6 1998 1871 1875 (Pubitemid 29008827)
42. S.S. Jick, E.S. Lieberman, M.U. Rahman, H.K. Choi Glucocorticoid use, other associated factors, and the risk of tuberculosis Arthritis Rheum 55 1 2006 19 26 (Pubitemid 43235123)
43. H.A. Kim, C.D. Yoo, H.J. Baek Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population Clin Exp Rheumatol 16 1 1998 9 13 (Pubitemid 28133475)
44. A. Lowin, J. Slater, J. Hall, G. Alperstein Cost effectiveness analysis of school based Mantoux screening for TB infection Aust N Z J Public Health 24 3 2000 247 253
45. T.R. Sterling, J. Bethel, S. Goldberg, P. Weinfurter, L. Yun, C.R. Horsburgh The scope and impact of treatment of latent tuberculosis infection in the United States and Canada Am J Respir Crit Care Med 173 8 2006 927 931
46. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial International Union Against Tuberculosis Committee on Prophylaxis Bull World Health Organ 60 4 1982 555 564
47. J. Ena, V. Valls Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis Clin Infect Dis 40 5 2005 670 676 (Pubitemid 40381339)
48. B.P. Linas, A.Y. Wong, K.A. Freedberg, C.R. Horsburgh Jr Priorities for screening and treatment of latent tuberculosis infection in the United States Am J Respir Crit Care Med 184 5 2011 590 601
49. E.M. Ruth, M.J. Kemper, E.P. Leumann, G.F. Laube, T.J. Neuhaus Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome J Pediatr 147 2 2005 202 207 (Pubitemid 41207834)
50. P. Tarshish, J.N. Tobin, J. Bernstein, C.M. Edelmann Jr Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children J Am Soc Nephrol 8 5 1997 769 776
51. Centers for Disease Control and Prevention, Division of Tuberculosis Elimination Reported tuberculosis in the United States http://www.cdc.gov/tb/ statistics/reports/2010/pdf/report2010.pdf Accessed April 20, 2012
52. M.H. Eckman, J. Rosand, S.M. Greenberg, B.F. Gage Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation Ann Intern Med 150 2 2009 73 83
53. B.F. Gage, A.B. Cardinalli, D.K. Owens The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life Arch Intern Med 156 16 1996 1829 1836 (Pubitemid 26295228)
54. N. Guo, C.A. Marra, F. Marra, S. Moadebi, R.K. Elwood, J.M. Fitzgerald Health state utilities in latent and active tuberculosis Value Health 11 7 2008 1154 1161
55. J. Tsevat, W.C. Taylor, J.B. Wong, S.G. Pauker Isoniazid for the tuberculin reactor: take it or leave it Am Rev Respir Dis 137 1 1988 215 220 (Pubitemid 18032856)
56. A. Piccoli, L. Pillon, P. Passerini, C. Ponticelli Therapy for idiopathic membranous nephropathy: tailoring the choice by decision analysis Kidney Int 45 4 1994 1193 1202 (Pubitemid 24234739)
57. Centers for Medicare & Medicaid Services (CMS) website Physician fee schedule http://www.cms.gov/pfslookup/02-PFSsearch.asp?agree=yes&next=Accept Accessed June 3, 2011
58. S.M. Finnell, J.C. Christenson, S.M. Downs Latent tuberculosis infection in children: a call for revised treatment guidelines Pediatrics 123 3 2009 816 822
59. C. Christy, M.L. Pulcino, B.P. Lanphear, K.M. McConnochie Screening for tuberculosis infection in urban children Arch Pediatr Adolesc Med 150 7 1996 722 726 (Pubitemid 26230872)
60. S.R. Salpeter, E.E. Salpeter Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis Infect Control Hosp Epidemiol 25 12 2004 1056 1061 (Pubitemid 39664732)
61. P.K. Dewan, J. Grinsdale, S. Liska, E. Wong, R. Fallstad, L.M. Kawamura Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay BMC Infect Dis 6 2006 47
62. Statistics on hospital stays Red Book 2009: Pharmacy's Fundamental Reference 113th ed. 2009 Thomson Reuters Montvale, NJ
63. US Department of Health and Human Services Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP) http://hcupnet.ahrq. gov/ Accessed March 6, 2010
64. S.R. Salpeter, G.D. Sanders, E.E. Salpeter, D.K. Owens Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis Ann Intern Med 127 12 1997 1051 1061 (Pubitemid 28012074)
65. J.L. Colquitt, J. Kirby, C. Green, K. Cooper, R.S. Trompeter The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review Health Technol Assess 11 21 2007 iii iv ix-xi, 1-93
66. C.R. Horsburgh Jr Priorities for the treatment of latent tuberculosis infection in the United States N Engl J Med 350 20 2004 2060 2067
67. C.R. Horsburgh Jr, M. O'Donnell, S. Chamblee Revisiting rates of reactivation tuberculosis: a population-based approach Am J Respir Crit Care Med 182 3 2010 420 425
68. P.A. LoBue, D.A. Enarson, T.C. Thoen Tuberculosis in humans and its epidemiology, diagnosis and treatment in the United States Int J Tuberc Lung Dis 14 10 2010 1226 1232
69. S. de Valliere, R.D. Barker Residual lung damage after completion of treatment for multidrug-resistant tuberculosis Int J Tuberc Lung Dis 8 6 2004 767 771 (Pubitemid 38747154)
70. R.S. Jung, J.R. Bennion, F. Sorvillo, A. Bellomy Trends in tuberculosis mortality in the United States, 1990-2006: a population-based case-control study Public Health Rep 125 3 2010 389 397
71. F. Fakhouri, N. Bocquet, P. Taupin Steroid-sensitive nephrotic syndrome: from childhood to adulthood Am J Kidney Dis 41 3 2003 550 557 (Pubitemid 36278371)
72. US Department of Labor Consumer Price Index inflation calculator http://www.bls.gov/data/inflation-calculator.htm Accessed March 8, 2010
73. B.J. McNeil, E. Keller, S.J. Adelstein Primer on certain elements of medical decision making N Engl J Med 293 5 1975 211 215
74. E. Arias United States Life Tables, 2001 Natl Vital Stat Rep 52 14 2004 1 38
75. P. Doubilet, C.B. Begg, M.C. Weinstein, P. Braun, B.J. McNeil Probabilistic sensitivity analysis using Monte Carlo simulation A practical approach Med Decis Making 5 2 1985 157 177 (Pubitemid 16130640)
76. E.J. Perez-Stable, R. Levin, A. Pineda, G. Slutkin Tuberculin skin test reactivity and conversions in United States- and foreign-born Latino children Pediatr Infect Dis 4 5 1985 476 479 (Pubitemid 15019910)
77. R. Wood, H. Liang, H. Wu Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa Int J Tuberc Lung Dis 14 4 2010 406 412
78. R. Diel, A. Nienhaus, R. Loddenkemper Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany Chest 131 5 2007 1424 1434 (Pubitemid 46762348)
79. R. Diel, P. Wrighton-Smith, J.P. Zellweger Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis Eur Respir J 30 2 2007 321 332 (Pubitemid 47194185)
80. M. Sester, G. Sotgiu, C. Lange Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis Eur Respir J 37 1 2011 100 111
81. S. Machingaidze, C.S. Wiysonge, Y. Gonzalez-Angulo The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis Pediatr Infect Dis J 30 8 2011 694 700
82. B.M. Bergamini, M. Losi, F. Vaienti Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents Pediatrics 123 3 2009 e419 e424